PTGX Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own PTGX shares is 340, representing 106.55% of the company's common stock.

WALLEYE CAPITAL LLC, in the last quarter, reduced its stake in PTGX by -27.67% restricting it's holding to 134.11 thousand shares of worth nearly $3.88M. EVERSEPT PARTNERS, LP also lessened -23.53% of the PTGX shares from its portfolio, reducing its holding to 411.48 thousand shares of worth $11.90M. CANDRIAM S.C.A. also shunned PTGX shares holding by -32.96% last quarter which brought its holding to 360 thousand shares worth $10.41M.

As per its latest 13F filing, FAIRMOUNT FUNDS MANAGEMENT LLC increased its stake in PTGX by 100% in the last quarter. The institutional holder raised its holding to 931.89 thousand shares having worth more than $26.96M. DEUTSCHE BANK AG\ also added 0.09% more shares of PTGX to its portfolio, raising its holding to 910.81 thousand shares of worth $26.35M. WOODLINE PARTNERS LP also increased its PTGX shares holding by 100% which brought its holding to 636.96 thousand shares worth $18.43M.

The insider with the most stakes in PTGX is Papanek Julie , director at the company. Additionally, PTGX stock is highly held by 10 percent owner JOHNSON & JOHNSON and 10 percent owner CANAAN X L.P. among others.

Company executives, directors, and other insiders own 1.9% percent of Protagonist Therapeutics, Inc.'s stock. Within the last six months, there have been 11 transaction(s) in which PTGX insiders have sold stock, totaling 271.92K shares. Insiders that have sold shares include ALI ASIF, MOLINA ARTURO MD, and GUPTA SUNEEL.

There have been 0 transaction(s) during the past 6-months in which Protagonist Therapeutics, Inc. insiders have bought stock, totalling 0 shares

Around 1.7M Protagonist Therapeutics, Inc. shares are held by insiders, which represents about 1.9% of PTGX stock.

PTGX director, Papanek Julie holds the largest portfolio of the company's shares. PTGX shares owned by Papanek total nearly 2.45 million.

WALLEYE CAPITAL LLC is the largest institutional owner in PTGX which holds 134.11 thousand shares worth $3.88M or 0.24% of the total PTGX shares outstanding followed by FAIRMOUNT FUNDS MANAGEMENT LLC with ownership of 931.89 thousand shares representing 1.64% of the PTGX ownership. DEUTSCHE BANK AG\ is the third largest stakeholder with 910.81 thousand shares or 1.6% of the ownership worth more than $26.35M.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the PTGX is concerned, it is a stock which is optionable.

Number of PTGX shares short is 3.67M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 59.60M shares of PTGX are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, PTGX has 44.38M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for PTGX is 5.54.